Moderna to Host Science Day on May 7, 2019 and Report First Quarter Financial Results on May 8, 2019

Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that it will host its annual Science Day for analysts and investors on Tuesday, May 7, 2019 at 8:00 a.m. ET in Cambridge, MA. Moderna also announced that it will report its first quarter 2019 financial results before the market opens on Wednesday, May 8, 2019 and, subsequently, host a conference call to discuss these results and provide a corporate update.

Science Day:

Modernas Science Day will feature presentations from Stephen Hoge M.D., president and Melissa Moore Ph.D., chief scientific officer of Modernas mRNA Research Platform with a focus on the Companys newest advances from its commitment to basic and applied sciences. Moderna will also host a tour of the Norwood manufacturing facility in the afternoon.

First Quarter 2019 Financial Results:

Modernas first quarter 2019 financial results and corporate update conference call will begin at 8:00 a.m. ET on May 8, 2019. To access the live conference call, please dial 866-922-5184 (domestic) or 409-937-8950 (international), and refer to conference ID 8273939.

Both events will be webcast live under Events & Presentations in the Investors section of the Moderna website at https://investors.modernatx.com/. The archived webcasts will be available on Modernas website approximately two hours after each event and will be available for 30 days following the events.

About Moderna

Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. mRNA medicines are designed to direct the bodys cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a broad spectrum of diseases. Modernas platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing the Company the capability to pursue in parallel a robust pipeline of new development candidates. Moderna is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and cardiovascular diseases, independently and with strategic collaborators.

Headquartered in Cambridge, Mass., Moderna currently has strategic alliances for development programs with AstraZeneca, Plc. and Merck, Inc., as well as the Defense Advanced Research Projects Agency (DARPA), an agency of the U.S. Department of Defense and the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). Moderna has been ranked in the top ten of Sciences list of top biopharma industry employers for the past four years. To learn more, visit www.modernatx.com.

Moderna Contacts:
Investors:
Lavina Talukdar
Head,
Investor Relations
617-209-5834
[email protected]

Media:
Jason Glashow
Head, Corporate Communications
617-674-5648
[email protected]